Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Bo Grundtmann"'
Autor:
Maj-Britt Jensen, Bo Grundtmann, Peer Christiansen, Anne Vibeke Lænkholm, Tove Filtenborg Tvedskov, Ann Knoop, Signe Korsgaard Skriver, Birgitte Bruun Rasmussen, Jürgen Handler, Bent Ejlertsen
Publikováno v:
Skriver, S K, Laenkholm, A-V, Rasmussen, B B, Handler, J, Grundtmann, B, Tvedskov, T F, Christiansen, P, Knoop, A S, Jensen, M-B & Ejlertsen, B 2018, ' Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG) ', Acta Oncologica, vol. 57, pp. 1-7 . https://doi.org/10.1080/0284186X.2017.1401228
INTRODUCTION: Neoadjuvant endocrine treatment (NET) is a low-toxicity approach to achieve operability in locally advanced breast cancer, and to facilitate breast conservation in early breast cancer, particular in patients with highly estrogen recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04cf3ecf5be74027a71b12f95d3263aa
https://pure.au.dk/portal/da/publications/neoadjuvant-letrozole-for-postmenopausal-estrogen-receptorpositive-her2negative-breast-cancer-patients-a-study-from-the-danish-breast-cancer-cooperative-group-dbcg(00e87aba-9155-43c4-aa58-bd0b14890dc5).html
https://pure.au.dk/portal/da/publications/neoadjuvant-letrozole-for-postmenopausal-estrogen-receptorpositive-her2negative-breast-cancer-patients-a-study-from-the-danish-breast-cancer-cooperative-group-dbcg(00e87aba-9155-43c4-aa58-bd0b14890dc5).html